![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C19H27NO |
Molar mass | 285.431 g·mol−1 |
3D model (JSmol) | |
| |
|
TH-PVP is a substituted cathinone derivative which has been sold as a designer drug. It was first identified by a forensic laboratory in Hungary in 2015, [2] but has subsequently been found in numerous other countries around the world including Spain, Belgium, Poland, Turkey and Brazil. [3] [4] [5] [6] [7] [8]
Pharmacological studies in vitro showed it to inhibit reuptake of the monoamine neurotransmitters, with about 10-fold selectivity for serotonin over norepinephrine and dopamine, whereas the drug did not induce monoamine release. [9] Despite its activity as a monoamine reuptake inhibitor, TH-PVP failed to produce stimulant effects in animals. [10]